Filter
292
Filtered Results: 292
Text search:
inactivated
vaccines
Featured
Recommendations
35
New Publications
83
Language
Document type
No document type
129
Guidelines
75
Studies & Reports
37
Fact sheets
18
Manuals
17
Strategic & Response Plan
7
Situation Updates
5
Training Material
3
Resource Platforms
1
Countries / Regions
Global
10
India
9
Pakistan
8
Germany
8
South Africa
7
Sierra Leone
6
Nigeria
6
Philippines
6
Afghanistan
5
Syria
5
Tanzania
5
Latin America and the Carribbean
5
Uganda
4
Kenya
4
Ukraine
4
Chile
4
Ethiopia
3
Nepal
3
Africa
3
Liberia
2
Congo, Democratic Republic of
2
Rwanda
2
Namibia
2
Myanmar / Burma
2
Yemen
2
East and Southern Africa
2
Middle East and North Africa
2
South–East Asia Region
2
Venezuela
2
Zimbabwe
1
Somalia
1
Iraq
1
Jordan
1
Lebanon
1
Zambia
1
Turkey
1
Egypt
1
China
1
Bangladesh
1
Malawi
1
Papua New Guinea
1
Argentina
1
Peru
1
Brazil
1
Colombia
1
Ecuador
1
Botswana
1
Bolivia
1
Libya
1
West and Central Africa
1
Eastern Europe and Central Asia
1
Western and Central Europe
1
Paraguay
1
Solomon Islands
1
Bhutan
1
Russia
1
Authors & Publishers
Publication Years
Category
Countries
82
Clinical Guidelines
41
Women & Child Health
14
Key Resources
7
Public Health
6
Pharmacy & Technologies
6
Capacity Building
1
Toolboxes
COVID-19
73
Polio
29
Rapid Response
20
Ebola
13
Pharmacy
13
Refugee
10
HIV
10
TB
10
NTDs
10
AMR
8
Cholera
7
Conflict
7
Zika
4
Natural Hazards
3
Planetary Health
3
Mental Health
2
Specific Hazards
1
Global Health Education
1
Health Financing Toolbox
1
NCDs
1
The purpose of this field guide is to provide comprehensive information on planning and implementing high-quality3 SIAs for injectable vaccines and highlight the opportunities to strengthen RI and surveillance. The guide uses measles–rubella SIAs...
The Guidance on National Deployment and Vaccination Planning is intended to help countries develop their plan for COVID-19 vaccine introduction.
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID...
3 February 2021
Vaccine- and vaccination-related crises require a communication response that is different from the communication strategies used to promote the benefits and importance of vaccines in general. This document presents the technical gu...
This module is part of the WHO series The Immunological Basis for Immunization, which was initially developed in 1993 as a set of eight modules, comprising one module on general immunology and seven modules each devoted to one of the vaccines recomm...
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covi...
The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards
the Immunization Agenda 2030 and pandemic prevention, prepared...
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage exist...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an...
This guide provides a comprehensive overview of essential information related to immunization, including technical information about vaccines, a review of immunization program management best practices, guidance on the delivery of immunization servi...
Update 2021; Immunization, Vaccines and Biologicals
Emerg Infect Dis. 2020 Jul [date cited]. https://doi.org/10.3201/eid2607.200915
Infection control instructions call for use of alcohol-based hand rub solutions to inactivate severe acute respiratory syndrome coronavirus 2. We determined the virucid...
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) h...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...
When situations occur in which unwanted events are rightly or wrongly connected with vaccination, they may erode confidence in vaccines and the authorities delivering them. This document presents the scientific evidence behind WHO’s recommendation...
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to financ...
